{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-030392","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-09-15T12:54:35+00:00","discovered_at":"2026-09-15T12:55:04.194078+00:00","generated_at":"2026-09-15T12:55:11.516048+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulse Biosciences completes 100-patient enrollment in PRECISE-BTN thyroid nodule study","bullets":["PRECISE-BTN study of nPulse Vybrance system fully enrolled 100 patients (expanded from original 50) by August 2026.","First enrolled patient completed final 12-month follow-up in August at Sarasota Memorial Health Care System.","Patients enrolled across three U.S. sites: Sarasota Memorial, NYU Langone Health, Weill Cornell Medicine in about 12 months.","Preliminary data expected at upcoming medical conference; full data after all patients complete 12-month follow-up."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-030392","json":"https://secwatch.observer/filing/0001437749-26-030392.json","markdown":"https://secwatch.observer/filing/0001437749-26-030392.md","text":"https://secwatch.observer/filing/0001437749-26-030392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926030392/0001437749-26-030392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926030392/plse20260827_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-15T12:55:11.516048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}